Related references
Note: Only part of the references are listed.A clinical trial of dextromethorphan in amyotrophic lateral sclerosis
O. Gredal et al.
ACTA NEUROLOGICA SCANDINAVICA (2010)
Design of phase II ALS clinical trials
David A. Schoenfeld et al.
AMYOTROPHIC LATERAL SCLEROSIS (2008)
Design, power, and interpretation of studies in the standard murine model of ALS
Sean Scott et al.
AMYOTROPHIC LATERAL SCLEROSIS (2008)
Altered macroautophagy in the spinal cord of S0D1 mutant mice
Liang Li et al.
AUTOPHAGY (2008)
Autophagy and amyotrophic lateral sclerosis: The multiple roles of lithium
Francesco Fornai et al.
AUTOPHAGY (2008)
Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis
S. Zoccolella et al.
NEUROLOGY (2008)
Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate
A. L. McCormick et al.
NEUROLOGY (2008)
Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis:: impact of SOD1 genotype
H. Zetterberg et al.
EUROPEAN JOURNAL OF NEUROLOGY (2007)
Elevation of MCP-1 and MCP-1/VEGF ratio in cerebrospinal fluid of amyotrophic lateral sclerosis patients
Tetsuya Nagata et al.
NEUROLOGICAL RESEARCH (2007)
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
Paul H. Gordon et al.
LANCET NEUROLOGY (2007)
Transgenic animal models of neurodegenerative diseases and their application to treatment development
Edward Rockenstein et al.
ADVANCED DRUG DELIVERY REVIEWS (2007)
Phase II/III randomized trial of TCH346 in patients with ALS
R. Miller et al.
NEUROLOGY (2007)
Muscle Nogo-A expression is a prognostic marker in lower motor neuron syndromes
Pierre-Francois Pradat et al.
ANNALS OF NEUROLOGY (2007)
A controlled study of reverse transcriptase in serum and CSF of HIV-negative patients with ALS
D. J. L. MacGowan et al.
NEUROLOGY (2007)
Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model
Francesco Paolo Di Giorgio et al.
NATURE NEUROSCIENCE (2007)
Good practice in the management of amyotrophic lateral sclerosis: Clinical guidelines. An evidence-based review with good practice points. EALSC Working Group
Peter Munch Andersen et al.
AMYOTROPHIC LATERAL SCLEROSIS (2007)
Early use of non-invasive ventilation prolongs survival in subjects with ALS
Noah Lechtzin et al.
AMYOTROPHIC LATERAL SCLEROSIS (2007)
Effect of non-invasive ventilation on survival, quality of life, respiratory function and cognition: A review of the literature
Sanne Piepers et al.
AMYOTROPHIC LATERAL SCLEROSIS (2006)
Creatine supplementation in Parkinson disease:: A placebo-controlled randomized pilot trial
A. Bender et al.
NEUROLOGY (2006)
Cerebrospinal fluid Flt3 ligand level in patients with amyotrophic lateral sclerosis
J. Ilzecka
ACTA NEUROLOGICA SCANDINAVICA (2006)
Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo
Xugang Xia et al.
NEUROBIOLOGY OF DISEASE (2006)
Trial of celecoxib in amyotrophic lateral sclerosis
Merit E. Cudkowicz et al.
ANNALS OF NEUROLOGY (2006)
Senataxin, the yeast Sen1p orthologue: Characterization of a unique protein in which recessive mutations cause ataxia and dominant mutations cause motor neuron disease
Ying-Zhang Chen et al.
NEUROBIOLOGY OF DISEASE (2006)
Identification of potential CSF biomarkers in ALS
GM Pasinetti et al.
NEUROLOGY (2006)
A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS
G Levy et al.
NEUROLOGY (2006)
Pentoxifylline in ALS - A double-blind, randomized, multicenter, placebo-controlled trial
V Meininger et al.
NEUROLOGY (2006)
Early signs of motoneuron vulnerability in a disease model system: Characterization of transverse slice cultures of spinal cord isolated from embryonic ALS mice
D Avossa et al.
NEUROSCIENCE (2006)
Truncated wild-type SOD1 and FALS-linked mutant SOD1 cause neural cell death in the chick embryo spinal cord
GD Ghadge et al.
NEUROBIOLOGY OF DISEASE (2006)
Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS
KL Ferrante et al.
NEUROLOGY (2005)
Production of monocyte chemoattractant protein-1 in amyotrophic lateral sclerosis
P Baron et al.
MUSCLE & NERVE (2005)
Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice
H Ryu et al.
JOURNAL OF NEUROCHEMISTRY (2005)
High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study
M Graf et al.
JOURNAL OF NEURAL TRANSMISSION (2005)
Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model
GS Ralph et al.
NATURE MEDICINE (2005)
Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives
AJ Steele et al.
NEUROLOGY (2005)
Clinical Trials in ALS: What Did We Learn from Recent Trials in Humans?
Vincent Meininger
NEURODEGENERATIVE DISEASES (2005)
The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis
M Demestre et al.
JOURNAL OF NEUROIMMUNOLOGY (2005)
Detection method of the adjacent motor neuronal death in an in vitro co-culture model of familial ALS-associated Cu/Zn superoxide dismutase
KS Park et al.
BIOTECHNOLOGY LETTERS (2004)
Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS
GM Alexander et al.
MOLECULAR BRAIN RESEARCH (2004)
Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials
V Meininger et al.
AMYOTROPHIC LATERAL SCLEROSIS (2004)
Unraveling the mechanisms involved in motor neuron degeneration in ALS
LI Bruijn et al.
ANNUAL REVIEW OF NEUROSCIENCE (2004)
Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis
PH Gordon et al.
NEUROLOGY (2004)
Increased lipid peroxidation in sera of ALS patients - A potential biomarker of disease burden
EP Simpson et al.
NEUROLOGY (2004)
A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis
ME Cudkowicz et al.
NEUROLOGY (2003)
Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients
J Ilzecka
ACTA NEUROLOGICA SCANDINAVICA (2003)
A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters
H Ryberg et al.
ACTA NEUROLOGICA SCANDINAVICA (2003)
Mutant dynactin in motor neuron disease
I Puls et al.
NATURE GENETICS (2003)
A randomized sequential trial of creatine in amyotrophic lateral sclerosis
GJ Groeneveld et al.
ANNALS OF NEUROLOGY (2003)
Differential vulnerability of cranial motoneurons in mouse models with motor neuron degeneration
C Haenggeli et al.
NEUROSCIENCE LETTERS (2002)
Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS
DB Drachman et al.
ANNALS OF NEUROLOGY (2002)
Increased plasma TGF-β 1 in patients with amyotrophic lateral sclerosis
K Houi et al.
ACTA NEUROLOGICA SCANDINAVICA (2002)
Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration
BH LaMonte et al.
NEURON (2002)
Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice
S Zhu et al.
NATURE (2002)
A pilot randomized trial of oxandrolone in inclusion body myositis
SB Rutkove et al.
NEUROLOGY (2002)
N-acetyl-L-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: effects on beta-amyloid secretion and tau phosphorylation
G Olivieri et al.
JOURNAL OF NEUROCHEMISTRY (2001)
A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2
S Hadano et al.
NATURE GENETICS (2001)
Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration
B Oosthuyse et al.
NATURE GENETICS (2001)
Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis
RG Miller et al.
NEUROLOGY (2001)
A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis
C Desnuelle et al.
AMYOTROPHIC LATERAL SCLEROSIS (2001)
Animal models of amyotrophic lateral sclerosis
A Doble et al.
AMYOTROPHIC LATERAL SCLEROSIS (2000)
Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn)
P Kennel et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2000)
Increased oxidative damage to DNA in ALS patients
M Bogdanov et al.
FREE RADICAL BIOLOGY AND MEDICINE (2000)
Changes in expression of NMDA receptor subunits in the rat lumbar spinal cord following neonatal nerve injury
L Virgo et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2000)
A randomized controlled trial of recombinant interferon beta-1a in ALS
E Beghi et al.
NEUROLOGY (2000)
Share Paper
